Video

Dr. Robak on the Inclusion Criteria of the RESONATE-2 Trial in CLL

Tadeusz Robak, MD, PhD, discusses the inclusion criteria of the the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Tadeusz Robak, MD, PhD, professor of hematology, Medical University of Lodz, chief, Department of Hematology, Copernicus Memorial Hospital, Lodz, Poland, discusses the inclusion criteria of the the phase 3 RESONATE-2 trial (NCT01722487) in chronic lymphocytic leukemia (CLL).

With up to 7 years of follow-up, findings from the RESONATE-2 trial demonstrated sustained progression-free survival and overall survival benefit with frontline, single-agent ibrutinib (Imbruvica) vs chlorambucil in patients with CLL. 

This study enrolled patients with previously untreated CLL, Robak explains. Major inclusion criteria stated that patients had to be at least 65 years of age, Robak explains. Patients were randomized 1:1 to receive ibrutinib vs chlorambucil.

Moreover, patients with 17p deletions were excluded from the study. At the time the study was planned, chlorambucil was a standard frontline therapy for patients with CLL, Robak explains. However, it was known that chlorambucil was was not an acceptable therapy for patients who harbored 17p deletions, Robak concludes.

Related Videos
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD